Jasbir Makker, Nikhitha Mantri, Harish K Patel, Hafsa Abbas, Ahmed Baiomi, Haozhe Sun, Yongsub Choi, Sridhar Chilimuri, Suresh Kumar Nayudu
{"title":"2019冠状病毒病住院患者消化道出血的发生率及死亡率影响","authors":"Jasbir Makker, Nikhitha Mantri, Harish K Patel, Hafsa Abbas, Ahmed Baiomi, Haozhe Sun, Yongsub Choi, Sridhar Chilimuri, Suresh Kumar Nayudu","doi":"10.2147/CEG.S318149","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients requiring hospitalization to critical care units are at a higher risk for gastrointestinal (GI) bleeding. Although severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection is predominantly a pulmonary disease, other serious manifestations including thromboembolic phenomenon are reported. Acute respiratory distress syndrome (ARDS) requiring mechanical ventilation, use of steroids and anticoagulation are all known to increase the risk of GI bleeding significantly.</p><p><strong>Aim: </strong>To study the incidence of GI bleeding and its impact on mortality in patients admitted with SARS-CoV-2.</p><p><strong>Methods: </strong>We retrospectively reviewed all patients admitted with SARS-CoV-2 from February 1, 2020 to April 15, 2020. We collected data including demographics, comorbid conditions, laboratory parameters, steroid and anticoagulant use. Coffee ground emesis, hematemesis, melena and hematochezia were defined as GI bleeding. All-cause mortality was reviewed for all patients included in the study. The relationship between GI bleeding and mortality was studied using logistic regression.</p><p><strong>Results: </strong>We had a total of 1206 patients hospitalized with SARS-CoV-2 infection with an all-cause mortality of 34% (n = 411). The overall incidence of GI bleeding was 3.1% (n = 37) with no significant difference between the patients who survived versus died during hospitalization (1.3% vs 1.5%, p = 0.77). Logistic regression analysis did not identify GI bleeding as an independent predictor of mortality. Therapeutic doses of anticoagulation were administered in 13.3% (n = 161) of patients, of which 6.8% (n = 11) developed GI bleeding. Patients were more likely to develop GI bleeding with use of therapeutic doses of anticoagulation (29.7% vs 12.8%, p = 0.003), steroids (37.8% vs 18.5%, p = 0.003) and mechanical ventilation (48.6% vs 30.4%, p = 0.018).</p><p><strong>Conclusion: </strong>Patients hospitalized with SARS-CoV-2 infection are at risk of gastrointestinal bleeding. Therapeutic doses of anticoagulation, mechanical ventilation and steroid use are significant risk factors for GI bleeding. However, GI bleeding did not significantly alter the mortality rates in SARS-CoV-2-infected patients.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"14 ","pages":"405-411"},"PeriodicalIF":2.5000,"publicationDate":"2021-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/49/ceg-14-405.PMC8517417.pdf","citationCount":"11","resultStr":"{\"title\":\"The Incidence and Mortality Impact of Gastrointestinal Bleeding in Hospitalized COVID-19 Patients.\",\"authors\":\"Jasbir Makker, Nikhitha Mantri, Harish K Patel, Hafsa Abbas, Ahmed Baiomi, Haozhe Sun, Yongsub Choi, Sridhar Chilimuri, Suresh Kumar Nayudu\",\"doi\":\"10.2147/CEG.S318149\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Patients requiring hospitalization to critical care units are at a higher risk for gastrointestinal (GI) bleeding. Although severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection is predominantly a pulmonary disease, other serious manifestations including thromboembolic phenomenon are reported. Acute respiratory distress syndrome (ARDS) requiring mechanical ventilation, use of steroids and anticoagulation are all known to increase the risk of GI bleeding significantly.</p><p><strong>Aim: </strong>To study the incidence of GI bleeding and its impact on mortality in patients admitted with SARS-CoV-2.</p><p><strong>Methods: </strong>We retrospectively reviewed all patients admitted with SARS-CoV-2 from February 1, 2020 to April 15, 2020. We collected data including demographics, comorbid conditions, laboratory parameters, steroid and anticoagulant use. Coffee ground emesis, hematemesis, melena and hematochezia were defined as GI bleeding. All-cause mortality was reviewed for all patients included in the study. The relationship between GI bleeding and mortality was studied using logistic regression.</p><p><strong>Results: </strong>We had a total of 1206 patients hospitalized with SARS-CoV-2 infection with an all-cause mortality of 34% (n = 411). The overall incidence of GI bleeding was 3.1% (n = 37) with no significant difference between the patients who survived versus died during hospitalization (1.3% vs 1.5%, p = 0.77). Logistic regression analysis did not identify GI bleeding as an independent predictor of mortality. Therapeutic doses of anticoagulation were administered in 13.3% (n = 161) of patients, of which 6.8% (n = 11) developed GI bleeding. Patients were more likely to develop GI bleeding with use of therapeutic doses of anticoagulation (29.7% vs 12.8%, p = 0.003), steroids (37.8% vs 18.5%, p = 0.003) and mechanical ventilation (48.6% vs 30.4%, p = 0.018).</p><p><strong>Conclusion: </strong>Patients hospitalized with SARS-CoV-2 infection are at risk of gastrointestinal bleeding. Therapeutic doses of anticoagulation, mechanical ventilation and steroid use are significant risk factors for GI bleeding. However, GI bleeding did not significantly alter the mortality rates in SARS-CoV-2-infected patients.</p>\",\"PeriodicalId\":10208,\"journal\":{\"name\":\"Clinical and Experimental Gastroenterology\",\"volume\":\"14 \",\"pages\":\"405-411\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2021-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/49/ceg-14-405.PMC8517417.pdf\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/CEG.S318149\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CEG.S318149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 11
摘要
背景:需要在重症监护病房住院的患者发生胃肠道出血的风险较高。虽然严重急性呼吸综合征冠状病毒2 (SARS-COV-2)感染主要是肺部疾病,但也有其他严重表现,包括血栓栓塞现象的报道。急性呼吸窘迫综合征(ARDS)需要机械通气,使用类固醇和抗凝剂都是已知的显著增加消化道出血的风险。目的:探讨SARS-CoV-2住院患者消化道出血的发生率及其对死亡率的影响。方法:回顾性分析2020年2月1日至2020年4月15日收治的所有SARS-CoV-2患者。我们收集的数据包括人口统计学、合并症、实验室参数、类固醇和抗凝血剂的使用。咖啡渣呕吐、呕血、黑黑和便血被定义为胃肠道出血。对研究中所有患者的全因死亡率进行了回顾。采用logistic回归分析消化道出血与死亡率的关系。结果:共有1206例SARS-CoV-2感染住院患者,全因死亡率为34% (n = 411)。胃肠道出血的总发生率为3.1% (n = 37),住院期间存活与死亡患者之间无显著差异(1.3% vs 1.5%, p = 0.77)。Logistic回归分析未发现胃肠道出血是死亡率的独立预测因子。13.3% (n = 161)的患者接受了治疗剂量的抗凝治疗,其中6.8% (n = 11)发生了胃肠道出血。使用治疗剂量的抗凝治疗(29.7% vs 12.8%, p = 0.003)、类固醇(37.8% vs 18.5%, p = 0.003)和机械通气(48.6% vs 30.4%, p = 0.018)的患者更容易发生胃肠道出血。结论:SARS-CoV-2感染住院患者存在消化道出血风险。抗凝治疗剂量、机械通气和类固醇使用是消化道出血的重要危险因素。然而,消化道出血并没有显著改变sars - cov -2感染患者的死亡率。
The Incidence and Mortality Impact of Gastrointestinal Bleeding in Hospitalized COVID-19 Patients.
Background: Patients requiring hospitalization to critical care units are at a higher risk for gastrointestinal (GI) bleeding. Although severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection is predominantly a pulmonary disease, other serious manifestations including thromboembolic phenomenon are reported. Acute respiratory distress syndrome (ARDS) requiring mechanical ventilation, use of steroids and anticoagulation are all known to increase the risk of GI bleeding significantly.
Aim: To study the incidence of GI bleeding and its impact on mortality in patients admitted with SARS-CoV-2.
Methods: We retrospectively reviewed all patients admitted with SARS-CoV-2 from February 1, 2020 to April 15, 2020. We collected data including demographics, comorbid conditions, laboratory parameters, steroid and anticoagulant use. Coffee ground emesis, hematemesis, melena and hematochezia were defined as GI bleeding. All-cause mortality was reviewed for all patients included in the study. The relationship between GI bleeding and mortality was studied using logistic regression.
Results: We had a total of 1206 patients hospitalized with SARS-CoV-2 infection with an all-cause mortality of 34% (n = 411). The overall incidence of GI bleeding was 3.1% (n = 37) with no significant difference between the patients who survived versus died during hospitalization (1.3% vs 1.5%, p = 0.77). Logistic regression analysis did not identify GI bleeding as an independent predictor of mortality. Therapeutic doses of anticoagulation were administered in 13.3% (n = 161) of patients, of which 6.8% (n = 11) developed GI bleeding. Patients were more likely to develop GI bleeding with use of therapeutic doses of anticoagulation (29.7% vs 12.8%, p = 0.003), steroids (37.8% vs 18.5%, p = 0.003) and mechanical ventilation (48.6% vs 30.4%, p = 0.018).
Conclusion: Patients hospitalized with SARS-CoV-2 infection are at risk of gastrointestinal bleeding. Therapeutic doses of anticoagulation, mechanical ventilation and steroid use are significant risk factors for GI bleeding. However, GI bleeding did not significantly alter the mortality rates in SARS-CoV-2-infected patients.